Editorial: early PSA-testing after radical prostatectomy—the truth behind the scenes

Adequate treatment of localized prostate cancer (PCa) remains challenging. Data from the U.S. National Cancer Institute reveals that PCa accounts for 9.9% of all new cancer diagnoses and 5.2% of all cancer deaths, accounting for 174,650 new cases and 31,620 deaths in 2019 (1). This data shows still a definite necessity for wide-ranging diagnostic, treatment, and follow-up options.